Companion Diagnostics Market worth $11.57 billion by 2031 | MarketsandMarkets™

▤ Summary

The companion diagnostics market is projected to rise from USD 6.31 billion in 2026 to USD 11.57 billion by 2031. Demand is being driven by precision medicine, targeted therapies, and biomarker-based treatment approaches, especially in oncology. The report highlights strong growth in assays, kits, and reagents, with PCR leading in 2025 and NGS expected to grow faster over the forecast period. North America holds the largest current share, while Asia Pacific is expected to expand more quickly. The article also lists major diagnostics, pharma, and life sciences companies active in the market.

▦ Linked Companies